Author

Irene Modesto

WORLDWIDE POST-MARKETING SAFETY SURVEILLANCE EXPERIENCE WITH TOFACITINIB IN ULCERATIVE COLITIS
WORLDWIDE POST-MARKETING SAFETY SURVEILLANCE EXPERIENCE WITH TOFACITINIB IN ULCERATIVE COLITIS

Irene Modesto  et al.

MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB: DATA FROM THE OCTAVE CLINICAL PROGRAMME
MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB: DATA FROM THE OCTAVE CLINICAL PROGRAMME

Irene Modesto  et al.

ASSOCIATION BETWEEN DURATION OF LATEST FLARE BEFORE INDUCTION TREATMENT WITH TOFACITINIB AND EFFICACY OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS
ASSOCIATION BETWEEN DURATION OF LATEST FLARE BEFORE INDUCTION TREATMENT WITH TOFACITINIB AND EFFICACY OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS

Irene Modesto  et al.

TREATMENT OUTCOME OF TOFACITINIB DOSE REDUCTION TO 5 MG BID VS REMAINING ON 10 MG BID IN PATIENTS WITH UC WHO WERE IN STABLE REMISSION ON 10 MG BID: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY
TREATMENT OUTCOME OF TOFACITINIB DOSE REDUCTION TO 5 MG BID VS REMAINING ON 10 MG BID IN PATIENTS WITH UC WHO WERE IN STABLE REMISSION ON 10 MG BID: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Irene Modesto  et al.

EFFICACY AND SAFETY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: AN UPDATE OF RESULTS FROM THE OCTAVE CLINICAL TRIALS
EFFICACY AND SAFETY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: AN UPDATE OF RESULTS FROM THE OCTAVE CLINICAL TRIALS

Irene Modesto  et al.

EARLY DISEASE CLEARANCE WITH ETRASIMOD AND CORRELATION WITH WEEK 52 OUTCOMES AND BIOMARKERS: A POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC TRIALS
EARLY DISEASE CLEARANCE WITH ETRASIMOD AND CORRELATION WITH WEEK 52 OUTCOMES AND BIOMARKERS: A POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC TRIALS

Irene Modesto  et al.

IMPACT OF ETRASIMOD ON BLOOD PRESSURE AND HYPERTENSION: DATA FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME
IMPACT OF ETRASIMOD ON BLOOD PRESSURE AND HYPERTENSION: DATA FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME

Irene Modesto  et al.

ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND SUBSTUDY
ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND SUBSTUDY

Irene Modesto  et al.

NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM
NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM

Irene Modesto  et al.

IMPACT OF PRIOR TUMOUR NECROSIS FACTOR INHIBITOR FAILURE AND PRIOR CORTICOSTEROID USE ON THE MAINTENANCE OF EFFICACY OF TOFACITINIB FOLLOWING DOSE REDUCTION IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION: 6-MONTH DATA FROM THE DOUBLE-BLI
IMPACT OF PRIOR TUMOUR NECROSIS FACTOR INHIBITOR FAILURE AND PRIOR CORTICOSTEROID USE ON THE MAINTENANCE OF EFFICACY OF TOFACITINIB FOLLOWING DOSE REDUCTION IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION: 6-MONTH DATA FROM THE DOUBLE-BLI

Irene Modesto  et al.

ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FRO
ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FRO

Irene Modesto  et al.

EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Irene Modesto  et al.

Item 1 - 12 / 12
1